Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease

Conclusions: The majority of the policies reviewed fail to adhere to the current AGA pathway recommendations for ulcerative colitis and CD. Further interventions are needed to better align policies with optimal evidence-based drug therapy.
Source: Inflammatory Bowel Diseases - Category: Gastroenterology Tags: IBD LIVE Articles Source Type: research